Mahankali Sumalatha, Kalava Jagadish, Garapati Yugandhar, Domathoti Bullarao, Maddumala Venkata Rao, Sundramurty Venkatesa Prabhu
Department of Mechanical Engineering, Velagapudi Ramakrishna Siddhartha Engineering College, Vijayawada, Andhra Pradesh 520007, India.
Deaprtment of CSE, Dr.A. P. J. Abdul Kalam University, Indor, India.
Evid Based Complement Alternat Med. 2022 May 9;2022:8621665. doi: 10.1155/2022/8621665. eCollection 2022.
The field of peptides and proteins has opened up new doors for plant-based medication development because of analytical breakthroughs. Enzymatic breakdown of plant-specific proteins yields bioactive peptides. These plant-based proteins and peptides, in addition to their in vitro and vivo outcomes for diabetes treatment, are discussed in this study. The secondary metabolites of vegetation can interfere with the extraction, separation, characterization, and commercialization of plant proteins through the pharmaceutical industry. Glucose-lowering diabetic peptides are a hot commodity. For a wide range of illnesses, bioactive peptides from flora can offer up new avenues for the development of cost-effective therapy options.
由于分析技术的突破，肽和蛋白质领域为基于植物的药物开发打开了新的大门。植物特异性蛋白质的酶促分解产生生物活性肽。本研究讨论了这些基于植物的蛋白质和肽，以及它们在糖尿病治疗中的体外和体内效果。植物的次生代谢产物可能会干扰制药行业对植物蛋白的提取、分离、表征和商业化。降血糖的糖尿病肽是热门商品。对于多种疾病，来自植物的生物活性肽可为开发经济高效的治疗方案提供新途径。
